Literature DB >> 26908355

Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development.

Michalis E Sarris1, Panagiotis Moulos2, Anna Haroniti2, Antonis Giakountis2, Iannis Talianidis3.   

Abstract

Smyd3 is a protein methyltransferase implicated in cancer development. Here we show that Smyd3 expression in mice is required for chemically induced liver and colon cancer formation. In these organs Smyd3 functions in the nucleus, stimulating the transcription of several key regulators involved in cell proliferation, epithelial-mesenchymal transition, the JAK/Stat3 oncogenic pathway, as well as the Myc and Ctnnb1 oncogenes. Smyd3 interacts with H3K4Me3-modified histone tails, which facilitates its recruitment to the core promoter regions of most active genes. Smyd3 binding density on target genes positively correlates with increased RNA polymerase-II density and transcriptional outputs. Despite its widespread distribution, the transcription-potentiating function of Smyd3 is restricted to a particular set of genes, whose expression is induced specifically during carcinogenesis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26908355     DOI: 10.1016/j.ccell.2016.01.013

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  55 in total

1.  Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3.

Authors:  Chuhui Huang; Si Si Liew; Grace R Lin; Anders Poulsen; Melgious J Y Ang; Brian C S Chia; Sin Yin Chew; Zekui P Kwek; John L K Wee; Esther H Ong; Priya Retna; Nithya Baburajendran; Rong Li; Weixuan Yu; Xiaoying Koh-Stenta; Anna Ngo; Sravanthy Manesh; Justina Fulwood; Zhiyuan Ke; Hwa Hwa Chung; Sugunavathi Sepramaniam; Xin Hui Chew; Nurul Dinie; May Ann Lee; Yun Shan Chew; Choon Bing Low; Vishal Pendharkar; Vithya Manoharan; Susmitha Vuddagiri; Kanda Sangthongpitag; Joma Joy; Alex Matter; Jeffrey Hill; Thomas H Keller; Klement Foo
Journal:  ACS Med Chem Lett       Date:  2019-05-23       Impact factor: 4.345

2.  LncRNA FENDRR represses proliferation, migration and invasion through suppression of survivin in cholangiocarcinoma cells.

Authors:  Xinglei Qin; Min Lu; Yajun Zhou; Gang Li; Zhaoyang Liu
Journal:  Cell Cycle       Date:  2019-04-14       Impact factor: 4.534

Review 3.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 4.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

5.  Novel insights into the oncogenic function of the SMYD3 lysine methyltransferase.

Authors:  Pawel K Mazur; Or Gozani; Julien Sage; Nicolas Reynoird
Journal:  Transl Cancer Res       Date:  2016-06       Impact factor: 1.241

6.  Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.

Authors:  Cheng-Lin Zhu; Qiang Huang
Journal:  Dig Dis Sci       Date:  2019-08-22       Impact factor: 3.199

7.  SMYD3-associated pathway is involved in the anti-tumor effects of sulforaphane on gastric carcinoma cells.

Authors:  Qing-Qing Dong; Qiu-Tong Wang; Lei Wang; Ya-Xin Jiang; Mei-Ling Liu; Hai-Jie Hu; Yong Liu; Hao Zhou; Hong-Peng He; Tong-Cun Zhang; Xue-Gang Luo
Journal:  Food Sci Biotechnol       Date:  2018-03-22       Impact factor: 2.391

8.  Mechanism of gene-specificity of oncogenic regulators.

Authors:  Panagiotis Moulos; Michalis E Sarris; Iannis Talianidis
Journal:  Cell Cycle       Date:  2016-05-31       Impact factor: 4.534

9.  Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.

Authors:  Noël J-M Raynal; Elodie M Da Costa; Justin T Lee; Vazganush Gharibyan; Saira Ahmed; Hanghang Zhang; Takahiro Sato; Gabriel G Malouf; Jean-Pierre J Issa
Journal:  Mol Cancer Ther       Date:  2016-12-15       Impact factor: 6.261

10.  VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.

Authors:  Cheng Liu; Li Liu; Kun Wang; Xiao-Feng Li; Li-Yuan Ge; Run-Zhuo Ma; Yi-Dong Fan; Lu-Chao Li; Zheng-Fang Liu; Min Qiu; Yi-Chang Hao; Zhen-Feng Shi; Chuan-You Xia; Klas Strååt; Yi Huang; Lu-Lin Ma; Dawei Xu
Journal:  Oncogene       Date:  2020-04-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.